Companies › Atsena Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Ophthalmology, Other; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ATSN-201 AAV gene therapy delivering hRS1 under hGRK1 promoter | RS1 | Phase 3 | X-linked Retinoschisis | Apr 2028 |
| ATSN-101 Gene therapy for GUCY2D mutations | GUCY2D | Phase 1 | Leber Congenital Amaurosis | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03920007 | ATSN-101 | Phase 1 | Leber Congenital Amaurosis | Ophthalmology | May 2027 |
| NCT05878860 | ATSN-201 | Phase 3 | X-linked Retinoschisis | Other | Apr 2028 |
–
EnnovaBio Novadip Biosciences Harmony Biosciences Management Bausch & Lomb Ocugen
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.